000130295 001__ 130295
000130295 005__ 20240228143422.0
000130295 0247_ $$2doi$$a10.1007/s11060-016-2133-x
000130295 0247_ $$2pmid$$apmid:27147083
000130295 0247_ $$2ISSN$$a0167-594X
000130295 0247_ $$2ISSN$$a0167-594x
000130295 0247_ $$2ISSN$$a1573-7373
000130295 037__ $$aDKFZ-2017-05374
000130295 041__ $$aeng
000130295 082__ $$a610
000130295 1001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b0$$eFirst author$$udkfz
000130295 245__ $$aIntraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors.
000130295 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2016
000130295 3367_ $$2DRIVER$$aarticle
000130295 3367_ $$2DataCite$$aOutput Types/Journal article
000130295 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522135236_11125
000130295 3367_ $$2BibTeX$$aARTICLE
000130295 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130295 3367_ $$00$$2EndNote$$aJournal Article
000130295 520__ $$aSystemic administration of etoposide is effective in treating metastatic, recurrent or refractory brain tumors, but penetration into the cerebrospinal fluid is extremely poor. This study was designed to determine the safety and toxicity profile of intraventricular etoposide administration and was affiliated with the prospective, multicenter, nonblinded, nonrandomized, multi-armed HIT-REZ-97 trial. The study enrolled 68 patients, aged 1.1-34.6 (median age 11 years). Adverse events that could possibly be related to intraventricular etoposide therapy were documented and analyzed. Intraventricular etoposide was simultaneously administered with either oral or intravenous chemotherapy in 426 courses according to three major schedules varying in dosing (0.25-1 mg), frequency of administration (bolus injection, every 12 or 24 h), course duration (5-10 days) and length of interval between courses (2-5 weeks). Potential treatment-related adverse effects included transient headache, seizures, infection of the reservoir, nausea and neuropsychological symptoms. Hematological side effects were not observed. One patient, with history of multiple prior therapies, who received long-term intraventricular and oral etoposide treatment developed acute myeloid leukemia as a secondary malignancy. Overall intraventricular etoposide is well tolerated. The results of this study have warranted a phase II trial to determine the effectiveness of this regimen in disease stages with very limited therapeutic options.
000130295 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000130295 588__ $$aDataset connected to CrossRef, PubMed,
000130295 7001_ $$aTippelt, Stephan$$b1
000130295 7001_ $$aSiegler, Nele$$b2
000130295 7001_ $$aReichling, Stefanie$$b3
000130295 7001_ $$aZimmermann, Martina$$b4
000130295 7001_ $$aMikasch, Ruth$$b5
000130295 7001_ $$aBode, Udo$$b6
000130295 7001_ $$aGnekow, Astrid$$b7
000130295 7001_ $$aPietsch, Torsten$$b8
000130295 7001_ $$aBenesch, Martin$$b9
000130295 7001_ $$aRutkowski, Stefan$$b10
000130295 7001_ $$aFleischhack, Gudrun$$b11
000130295 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-016-2133-x$$gVol. 128, no. 3, p. 463 - 471$$n3$$p463 - 471$$tJournal of neuro-oncology$$v128$$x1573-7373$$y2016
000130295 909CO $$ooai:inrepo02.dkfz.de:130295$$pVDB
000130295 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130295 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000130295 9141_ $$y2016
000130295 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000130295 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2015
000130295 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130295 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130295 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130295 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130295 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130295 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130295 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130295 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130295 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000130295 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000130295 980__ $$ajournal
000130295 980__ $$aVDB
000130295 980__ $$aI:(DE-He78)B062-20160331
000130295 980__ $$aUNRESTRICTED